bêta
IA Trial Radar
L'essai clinique NCT07455331 (LANCE) pour Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC) est pas encore en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Flash Radiotherapy for Skin Cancer (LANCE) Phase II 60 Dose unique

Pas encore en recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT07455331 (LANCE) est conçu pour étudier le traitement de Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC). Il s'agit d'une étude interventionnel en Phase II. Son statut actuel est : pas encore en recrutement. Le recrutement est prévu pour commencer le 23 mars 2026, avec un objectif de 60 participants. Dirigée par Jules Bordet Institute, l'étude devrait être terminée d'ici le 23 décembre 2030. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 6 mars 2026.
Résumé succinct
The goal of this clinical investigation is to describe and compare the toxicity and efficacy of an experimental radiotherapy, named FLASH therapy, to conventional radiotherapy for subjects suffering from localized Cutaneous Squamous Cell Carcinoma (cSCC) and Basal Cell Carcinoma (BCC). FLASH therapy can deliver the irradiation dose within milliseconds instead of the minutes commonly required in conventional radiother...Afficher plus
Titre officiel

Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Participants With Localized Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Pathologies
Cutaneous Squamous Cell Carcinoma (CSCC)Basal Cell Carcinoma (BCC)
Autres identifiants de l'étude
  • LANCE
  • IJB-LANCE-2025
Numéro NCT
NCT07455331
Date de début (réel)
2026-03-23
Dernière mise à jour publiée
2026-03-06
Date de fin (estimée)
2030-12-23
Inscription (estimée)
60
Type d'étude
Interventionnel
PHASE
Phase II
Statut
Pas encore en recrutement
Mots clés
radiotherapy
FLASH
skin cancer
Objectif principal
Traitement
Méthode d'allocation
Randomisé
Modèle d'intervention
Parallèle
Masquage
Simple aveugle
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalFLASH radiotherapy
22 Gy single dose FLASH radiotherapy
FLASH radiotherapy
FLASH therapy is delivered almost instantaneously (in milliseconds), as opposed to conventional radiotherapy, which is delivering the dose in minutes.
Comparateur actifConventional radiotherapy
22 Gy single dose conventional radiotherapy
Radiothérapie conventionnelle
Standard of Care
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Evaluate the safety of FLASH radiotherapy
Safety of FLASH radiotherapy measured by the collection of ≥ grade 3 skin toxicity AEs (CTCAE v6.0) ≤ 6 weeks after radiotherapy. Assessment will be performed by physical examination at 3,4,6 weeks post treatment (It may be necessary to perform these procedures at unscheduled time points if deemed clinically necessary by the investigator).
"From enrollment until 6 weeks after radiotherapy"
hierarchically tested efficacy of FLASH radiotherapy
Hierarchically tested efficacy measured by local control rate at 1-year. Local control rate is censured by any in field local relapse up to one-year post randomization (Tumor response evaluated during physical exam). Assessment will be performed by physical exam and Blinded Imaging Central Review (BICR) of photographs at 3,4,6 weeks and 3,6,12 months.
"From enrollment until 1-year post randomization"
Critère secondaire d'évaluation
Critères d'évaluationDescription de la mesurePériode
Evaluate tumor response
Tumor response Assessment will be performed by physical exam and Blinded Imaging Central Review (BICR) of photographs at 3,4,6 weeks and 3,6,12 months post treatment
"From enrolment until 12 months post-treatment"
Evaluate acute side effects "in the radiation field"
Acute side effects "in the radiation field" defined by any toxicity (CTCAE v6.0), until 3 months after the irradiation date. Assessment will be performed by physical exam, Blinded Imaging Central Review (BICR) of photographs at 3,4,6 weeks post treatment and OCT (optical coherence tomography) at 4 weeks post treatment.
"From enrollment until 6 weeks after the irradiation date"
Evaluate late side effects "in the radiation field"
Late side effects "in the radiation field" (within 3 to 12 months post-treatment) (CTCAE v6.0). Assessment will be performed by physical exam, Blinded Imaging Central Review (BICR) of photographs 3,6,12 months post treatment and OCT (optical coherence tomography) at 6 and 12 months.
"From 3 months post treatment until 12 months post treatment"
Assistant à la participation
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
60 Years
Sexes éligibles
Tous
  1. Signed study Informed Consent Form
  2. Karnofsky Performance Status (KPS) ≥ 60
  3. Age ≥ 60 years
  4. Participants with histologically proven cSCC; or participants with BCC either histologically proven or proven by non-invasive imaging: either OCT, LC-OCT or RCM
  5. Participants requiring radiotherapy treatment according to the dermato-oncology tumor board: participants who cannot undergo surgical procedure or participants who decline surgical resection, and/or anatomical locations where surgery can compromise function or cosmesis.
  6. T1-N0 lesions (TNM UICC, 8th Edition)
  7. Lesions should be at least 4 cm apart if treated with 2 different modalities (including surgical treatment of lesions). Lesions should not be located on the face, except on the forehead, above a line situated 1 cm above the eyebrows. Lesions located on the scalp can be treated
  8. In cases of prior intervention within the target area, the treated lesion must be located at a distance of > 4 cm from the previous site.

  1. Previous radiotherapy in the treated area or a history of radiation therapy within 4 cm of the lesion to be treated
  2. Concomitant auto-immune disease with skin lesions
  3. Concomitant use of radio-sensitizer drug
  4. Cognitive disorders not compatible with the signature of informed consent or that may compromise compliance with the requirements of the study
  5. Current, recent (within 10 days prior to start of study treatment), or planned participation in an experimental drug study (before EOT visit)
  6. Concomitant use of systemic or immunochemotherapy for skin cancer(s)
  7. Concomitant use of systemic chemotherapy for a cancer other than the skin cancer(s)
  8. Topical antitumoral treatment is prohibited within the radiation field except after a mandatory 4-weeks washout period.
  9. Any active cutaneous infection within the irradiation field (except if completely resolved prior to the initiation of radiotherapy).
  10. Uncontrolled intercurrent comorbidities that may impair wound healing including Diabetes Mellitus (HbA1c > 8.5% or evidence of active diabetic ulceration), Chronic Venous Insufficiency with active venous ulcers, or severe (Grade 3+) oedema in the treatment field.
Jules Bordet Institute logoJules Bordet Institute
Contact central de l'étude
Contact: Antoine Desmet, Dr, +32 2 5413032, [email protected]
Contact: Sophie Lepannetier, PhD, +32 02 541 3456, [email protected]
1 Centres de l'étude dans 1 pays

Anderlecht

Institut Jules Bordet, Brussels, Anderlecht, 1070, Belgium